- Home
- GOF vs TWST Comparison
GOF vs TWST Comparison
Compare GOF & TWST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOF
- TWST
- Stock Information
- Founded
- GOF 2006
- TWST 2013
- Country
- GOF United States
- TWST United States
- Employees
- GOF N/A
- TWST N/A
- Industry
- GOF Finance/Investors Services
- TWST Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GOF Finance
- TWST Health Care
- Exchange
- GOF Nasdaq
- TWST Nasdaq
- Market Cap
- GOF 2.5B
- TWST 2.6B
- IPO Year
- GOF N/A
- TWST 2018
- Fundamental
- Price
- GOF $15.56
- TWST $39.26
- Analyst Decision
- GOF
- TWST Buy
- Analyst Count
- GOF 0
- TWST 10
- Target Price
- GOF N/A
- TWST $52.50
- AVG Volume (30 Days)
- GOF 789.2K
- TWST 1.1M
- Earning Date
- GOF 01-01-0001
- TWST 05-01-2025
- Dividend Yield
- GOF 15.42%
- TWST N/A
- EPS Growth
- GOF N/A
- TWST N/A
- EPS
- GOF N/A
- TWST N/A
- Revenue
- GOF N/A
- TWST $330,189,000.00
- Revenue This Year
- GOF N/A
- TWST $22.62
- Revenue Next Year
- GOF N/A
- TWST $17.76
- P/E Ratio
- GOF N/A
- TWST N/A
- Revenue Growth
- GOF N/A
- TWST 25.85
- 52 Week Low
- GOF $10.96
- TWST $27.41
- 52 Week High
- GOF $16.76
- TWST $60.90
- Technical
- Relative Strength Index (RSI)
- GOF 44.08
- TWST 41.99
- Support Level
- GOF $15.49
- TWST $40.50
- Resistance Level
- GOF $15.93
- TWST $44.94
- Average True Range (ATR)
- GOF 0.16
- TWST 2.38
- MACD
- GOF -0.03
- TWST 0.17
- Stochastic Oscillator
- GOF 32.73
- TWST 26.32
About GOF Guggenheim Strategic Opportunities Fund of Beneficial Interest
Guggenheim Strategic Opportunities Fund is a diversified, closed-end management investment company. The investment objective of the firm is to maximize total return through a combination of current income and capital appreciation. The Fund seeks to combine a credit-managed fixed-income portfolio with access to a diversified pool of alternative investments and equity strategies.
About TWST Twist Bioscience Corporation
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to realize opportunities ahead rapidly. Geographically, it derives a majority of its revenue from the United States.